Tempus AI acquires Paige
Aug. 28, 20205—Tempus AI is acquiring Paige for $81.25 million.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Randox Labs expands its operations in West Virginia
Aug. 27, 2025—Randox Laboratories plans to expand its facility in Jefferson County, W. Va., from a 48-person sales and distribution operation to a full-scale production laboratory.
SehaMed, New Day Dx to launch ColoHealth in the Middle East
Aug. 26, 2025—SehaMed Global (Bristol, England) announced a strategic distribution agreement with New Day Diagnostics, of Knoxville, Tenn., to bring ColoHealth, an FDA-approved blood test for the early detection of colorectal cancer, to patients in Saudi Arabia, the United Arab Emirates, and other countries in the Middle East.
Ifinatamab deruxtecan gets breakthrough therapy designation
Aug. 25, 2025—Ifinatamab deruxtecan (I-DXd) has been granted breakthrough therapy designation by the FDA for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.
ArteraAI Prostate gets breakthrough device designation
Aug. 18, 2025—The FDA has granted breakthrough device designation to Artera’s ArteraAI Prostate, an AI precision medicine tool intended to assist clinicians with risk-based decisions for patients with localized prostate cancer.
QuidelOrtho launches certified analyzer program
Aug. 15, 2025—QuidelOrtho Corp. has launched a certified analyzer program designed to expand access to high-quality diagnostic testing in rural and community hospitals across the United States.
Bio-Rad launches Unity Next Peer QC in Asia-Pacific region
Aug. 14, 2025—Bio-Rad Laboratories has launched its Unity Next Peer QC data management software throughout the Asia-Pacific region.
Pathology Visions 2025
Aug. 13, 2025—Pathology Visions 2025 (PathVisions25) is the premier annual meeting of the Digital Pathology Association (DPA), bringing together over 850 global health care professionals and industry innovators.
FDA clears assay to detect CTX-M enzymes
Aug. 12, 2025—Hardy Diagnostics announced FDA clearance of the NG-Test CTX-M Multi, an in vitro diagnostic immunoassay for the qualitative detection of CTX-M enzymes (groups 1, 2, 8, 9, and 25) from pure colonies of Enterobacterales suspected of extended-spectrum beta-lactamase production.
Thermo Fisher nabs FDA approval for NSCLC CDx
Aug. 11, 2025—Thermo Fisher Scientific has received FDA approval for its Oncomine Dx Target test as a companion diagnostic to identify patients who may be candidates for zongertinib (Hernexeos, Boehringer Ingelheim), a tyrosine kinase inhibitor.